Atezolizumab + Rucaparib
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecologic Neoplasms
Conditions
Gynecologic Neoplasms
Trial Timeline
Apr 27, 2017 → Aug 11, 2020
NCT ID
NCT03101280About Atezolizumab + Rucaparib
Atezolizumab + Rucaparib is a phase 1 stage product being developed by Roche for Gynecologic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03101280. Target conditions include Gynecologic Neoplasms.
What happened to similar drugs?
0 of 2 similar drugs in Gynecologic Neoplasms were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03101280 | Phase 1 | Completed |
Competing Products
13 competing products in Gynecologic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMGN151 + Carboplatin + Bevacizumab + Olaparib | AbbVie | Phase 2 | 42 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 21 |
| Pembrolizumab | Merck | Phase 1 | 29 |
| Vigil + Atezolizumab | Roche | Phase 2 | 35 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 35 |
| Oral apixaban + Subcutaneous enoxaparin | Bristol Myers Squibb | Phase 2 | 35 |
| AK112 | Akeso | Phase 2 | 35 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 40 |
| Floseal | Baxter | Phase 3 | 33 |
| FloSeal application | Baxter | Pre-clinical | 23 |
| IPH2201 | Innate Pharma | Phase 1 | 19 |
| Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) | Alaunos Therapeutics | Phase 1/2 | 14 |
| Neoantigen specific TCR-T cell drug product | Alaunos Therapeutics | Pre-clinical | 16 |